A program to support emotional and physical health in patients with acute leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of a novel intervention called Emotion and Symptom-focused Engagement (EASE) for individuals newly diagnosed with acute leukemia. Participants will be divided into two groups: one receiving standard care and the other receiving standard care plus the EASE intervention, which includes tailored psychotherapy and symptom screening with referrals to palliative care. The aim is to reduce psychological distress and physical symptom burden during the initial treatment phase. The study builds on preliminary findings suggesting that EASE may improve patient outcomes compared to usual care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Newly diagnosed AL (acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) chronic myelogenous leukemia (CML) in blast crisis; T-cell leukemia lymphoma (TLL), and AL of ambiguous lineage) and is recruited up to 1 week prior to hospital admission or within 2 weeks of hospital admission. For patients diagnosed with a mixed phenotype AL, the dominant sub-type must be identified for stratification purposes.
* Receiving or expected to receive induction therapy with curative intent at the time of recruitment.
* Age ≥ 18 years.
* Ability to pass the cognitive screening test at the time of recruitment (Short Orientation-Memory-Concentration Test (SOMC) score ≥ 20), unless deemed suitable at the CRA's discretion (e.g. in extenuating circumstances such as interruptions during the administration of the measure or when patients report a learning disability that can influence the results).
* Patient is fluent in English and is able (i.e. sufficiently literate and competent) and willing to complete the baseline questionnaires in English. Ability but unwillingness to complete the baseline questionnaires will make the patient ineligible.

Exclusion Criteria:

* Major communication difficulties at the time of recruitment, as assessed by the research team (e.g. severe hearing impairment or inability to speak).
* Receiving on-site (in hospital) psychological/psychiatric counseling at the time of recruitment.
* Receiving on-site (in hospital) palliative care services at the time of recruitment.
* A diagnosis of acute promyelocytic leukemia.

Where it's running

• Juravinski Cancer Centre at Hamilton Health Sciences
  Hamilton, Ontario, Canada Recruiting
• Kingston Health Sciences Centre
  Kingston, Ontario, Canada Recruiting
• Ottawa Hospital Research Institute
  Ottawa, Ontario, Canada Recruiting
• Odette Cancer Centre
  Toronto, Ontario, Canada Recruiting
• University Health Network
  Toronto, Ontario, Canada Recruiting
• Regional Health Authority B, Zone 2
  Saint John, New Brunswick, Canada Not yet recruiting

Study contacts

• Study coordinator: Harriet Richardson
• Email: hrichardson@ctg.queensu.ca
• Phone: 613-533-6430

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Menin inhibitors in pediatric relapsed or refractory acute leukemia

  This study looks at kids with relapsed or treatment-resistant acute leukemia who have specific genetic changes and are treated with menin inhibitors to see how they fare.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07898436

• Artistic and movement activities to help anxiety in kids with ALL

  Kids aged 8–13 with acute lymphoblastic leukemia test whether a 16-session art and movement program can reduce anxiety compared with standard care.

  Recruiting Phase 3 Children's Cancer Hospital Egypt 57357 · Cairo, Cairo Governorate · NCT07878065

• Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma

  Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07634653

• QUAIL-100 in kids and young adults after stem cell transplant with high-risk blood cancers

  This study tests QUAIL-100 in pediatric and young adult patients who have high-risk acute leukemia or myelodysplastic syndrome and have already received a partially matched stem cell transplant.

  Recruiting Phase 1 Laguna Biotherapeutics, Inc. · Palo Alto, California · NCT07573111

• Thiotepa-based Conditioning With Reduced Post-Transplant Cyclophosphamide for Allogeneic Stem Cell Transplant in High-Risk Blood C cancers

  This phase 1 trial tests a Thiotepa, Busulfan, and Fludarabine conditioning regimen with de-escalated post-transplant cyclophosphamide to see if it can improve outcomes after allogeneic stem cell transplantation for high-risk blood cancers.

  Recruiting Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07565220

• Menin inhibitor maintenance after allogeneic stem cell transplant

  This project will try menin inhibitor maintenance to see if it helps people with acute leukemia after allogeneic stem cell transplant who have KMT2A or related gene changes.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07559695

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.